🏛️ Verified NIH Record • Updated 2021-02-04
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) (NCT04065490)
A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)
🔵 Active, Not Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: LumiThera, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
Who can join: Review the eligibility criteria below.
Location: Retina Vitreous Associates Medical Group — Beverly Hills, California
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Retina Vitreous Associates Medical Group — Beverly Hills, California
- Stanford University — Palo Alto, California
- Florida Eye Clinic — Altamonte Springs, Florida
- Cumberland Valley Retina Consultants — Hagerstown, Maryland
- Mid Atlantic Retina — Cherry Hill, New Jersey
- New York Ear and Eye Infirmary — New York, New York
- Duke Eye Center — Durham, North Carolina
- Cumberland Valley Retina Consultants — Chambersburg, Pennsylvania
- Gulf Coast Eye Institute — McAllen, Texas
- Retina Consultants of Houston — The Woodlands, Texas
- Retina Center Northwest — Silverdale, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dry Age-related Macular Degeneration
- Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study — Glendale, California
- Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) — Beverly Hills, California
- Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD — Phoenix, Arizona
- A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy) — Beverly Hills, California
- Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration — Baltimore, Maryland
Explore by condition: All Dry Age-related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.